Atlanta, Georgia (PRWEB) November 15, 2016
Three medications showing great promise for treating Alzheimer’s and dementia are in clinical trials at NeuroTrials Research (NTR) midway through November, the month in which the entire nation turns purple to commemorate National Alzheimer’s Disease Awareness and Family Caregivers Month.
President Ronald Reagan tapped November as National Alzheimer’s Disease Awareness Month in 1983. At that time, less than two million Americans had the disease; today, more than 5 million are living with Alzheimer’s. Every 66 seconds someone in the U.S. develops the disease which will cost $236 billion in 2016 alone. In 2015, more than 15 million caregivers provided an estimated 18.1 billion hours of unpaid care for loved ones with Alzheimer’s.
In Atlanta, Sandy Springs-based NTR is currently conducting clinical trials on three potential medications for Alzheimer’s. More than 15 volunteers are currently participating in the studies, and all are enrolling more patients on an ongoing basis.
MINDSET is the name of one Alzheimer’s worldwide clinical trial in which NTR study participants are given a medication showing potential to be the first new FDA-approved drug for Alzheimer’s in more than 10 years. MINDSET studies whether the medication can slow the progression of Alzheimer’s when taken together with Donepezil, the generic form of Aricept, today’s most commonly prescribed Alzheimer’s medication. NTR is accepting additional study candidates ages 50 to 85 who show mild to moderate Alzheimer’s or dementia.
A second clinical trial seeking participants examines the link between agitation and Alzheimer’s disease. Various triggers can cause unpredictable outbursts in Alzheimer’s and dementia patients including verbal or physical outbursts, emotional distress, restlessness, pacing and even shredding tissues. NTR is studying treatment for agitation in patients who are 50-90 years old, have a diagnosis of probable Alzheimer’s Disease, experience moderate to severe agitation that interferes with daily routine, have a caregiver who is able and willing to comply with all required study procedures, and are otherwise in good health.
The third Alzheimer’s study at NTR seeks to determine the safety and effectiveness of an investigational study drug for insomnia in patients with Alzheimer’s disease. A frequent cause of concern for caregivers, Alzheimer’s or dementia patients often experience disruption to their sleep schedule. Currently scientists do not understand the link between Alzheimer’s disease and sleep. NTR is seeking volunteers age 50-90 with Alzheimer’s disease who have difficulty getting to sleep or staying asleep.
Learn more at http://www.NeuroTrials.com or call 404-851-9934 for more information.
About NeuroTrials Research
Founded in 1997, NeuroTrials Research (NTR) is a nationally-recognized early- to late-phase inpatient and outpatient clinical research site located in the Atlanta suburb of Sandy Springs. Focused on neurological disorders including Alzheimer’s, migraine headaches, Parkinson’s and various sleep-related conditions, the research facility has a 12,000 square foot facility that includes a 15-bed, state-of-the-art sleep lab and inpatient clinical research unit designed specifically for the comfort and safety of clinical trial participants. Dr. Russell Rosenberg, PhD, D.ABSM, is NTR’s founder and CEO and a former chairman of the National Sleep Foundation. Learn more at http://www.NeuroTrials.com or call 404-851-9934 for more information.
About Clinical Trials
More than 2,500 volunteers have been study participants in 175+ clinical trials at NeuroTrials Research. Qualified study participants receive free medical evaluations, treatment and are compensated for their time and travel. Nationwide, 2.3 million people participate in 80,000 U.S. clinical trials annually; 70% of participants say they would volunteer again; approximately 178,000 studies enroll worldwide annually; more than 120 new drugs get FDA approval each year; and it takes 10 years of lab study before a treatment can be tested on humans.
# # #